Current Antiretroviral Treatment Among People With Human Immunodeficiency Virus in the United States: Findings from the Centers for AIDS Research Network of Integrated Clinic Systems Cohort.

Jimmy Ma,Bridget M Whitney,Ronnie M Gravett,Laura Bamford,Kenneth H Mayer,Sonia Napravnik,Greer A Burkholder,Jeffrey M Jacobson,Jeffrey Martin,Richard D Moore,Heidi M Crane,Michael S Saag,Robin M Nance,Joseph J Eron,Mari M Kitahata,Edward R Cachay,Jeanne Keruly,Katerina Christopoulos,Joseph A C Delaney

doi:10.1093/cid/ciac086

Current Antiretroviral Treatment Among People With Human Immunodeficiency Virus in the United States: Findings from the Centers for AIDS Research Network of Integrated Clinic Systems Cohort.

Jimmy Ma, Bridget M Whitney + Show 17 more

Open Access

https://doi.org/10.1093/cid/ciac086

Copy DOI

Journal: Clinical Infectious Diseases	Publication Date: Feb 3, 2022
Citations: 2

Affiliation: University of Washington, University of Alabama, University of California, San Diego, Fenway Health, University of North Carolina at Chapel Hill, Case Western Reserve University, University of California, San Francisco, Johns Hopkins University, University of Manitoba

#Second-generation Integrase Strand Transfer Inhibitors #Centers For AIDS Research Network + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Among 14 049 people with human immunodeficiency virus in care in 2019-2020, 96% were treated with antiretroviral therapy (ART). Current antiretroviral treatment patterns highlight high uptake of guideline-recommended ART regimens including second-generation integrase strand transfer inhibitors (dolutegravir and bictegravir) and tenofovir alafenamide, especially in antiretroviral-naive individuals initiating ART.

Full Text